A Randomized, Single-Blind, Placebo-Controlled, Single Ascending Dose Study to Determine the Exposure-Response Relationship Between Abemaciclib and QT Interval in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 17 Aug 2016
At a glance
- Drugs Abemaciclib (Primary) ; Loperamide
- Indications Breast cancer; Mantle-cell lymphoma; Non-small cell lung cancer; Solid tumours
- Focus Adverse reactions
- Sponsors Eli Lilly
- 11 Aug 2016 Status changed from recruiting to completed.
- 15 Jun 2016 Planned End Date changed from 1 Jun 2016 to 1 Nov 2016.
- 15 Jun 2016 Planned primary completion date changed from 1 Jun 2016 to 1 Nov 2016.